Advanced search
Publication Cover
Postgraduate Medicine Volume 127, 2015 - Issue 2
Submit an article Journal homepage
2,404
Views
14
CrossRef citations to date
0
Altmetric
Original Research

Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis

Michael J. KorenJacksonville Center for Clinical Research, Jacksonville, FL, USACorrespondence[email protected]
,
Eli M. RothSterling Research Group, Cincinnati, OH, USA
,
James M. McKenneyVirginia Commonwealth University and National Clinical Research, Inc., Richmond, VA, USA
,
Daniel GipeRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
,
Corinne HanotinSanofi, Paris, France
,
Anne-Catherine FerrandSanofi, Paris, France
,
Richard WuRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
&
Robert DufourInstitut de Recherches Cliniques de Montréal, University of Montreal, Montreal, Canada
 show all
Pages 125-132 | Received 15 Oct 2014, Accepted 12 Dec 2014, Published online: 22 Jan 2015

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Cezary Wójcik. (2017) Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. Postgraduate Medicine 129:8, pages 801-810.
Read now
Sandy Elbitar, Petra El Khoury, Youmna Ghaleb, Jean-Pierre Rabès, Mathilde Varret, Nabil G. Seidah, Catherine Boileau & Marianne Abifadel. (2016) Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). Expert Opinion on Therapeutic Patents 26:12, pages 1377-1392.
Read now
Željko Reiner. (2015) PCSK9 inhibitors – past, present and future. Expert Opinion on Drug Metabolism & Toxicology 11:10, pages 1517-1521.
Read now

Articles from other publishers (11)

Konstantinos Pamporis, Paschalis Karakasis, Spyridon Simantiris, Marios Sagris, Konstantinos I. Bougioukas, Nikolaos Fragakis & Dimitrios Tousoulis. (2024) Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias’ treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network metaanalysis. Clínica e Investigación en Arteriosclerosis 36:2, pages 86-100.
Crossref
Konstantinos Pamporis, Paschalis Karakasis, Spyridon Simantiris, Marios Sagris, Konstantinos I. Bougioukas, Nikolaos Fragakis & Dimitrios Tousoulis. (2024) Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias’ treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network metaanalysis. Clínica e Investigación en Arteriosclerosis (English Edition) 36:2, pages 86-100.
Crossref
Zuzana Zafarová. (2021) Pro a předem prohraný souboj proti PCSK9 inhibitorům. Vnitřní lékařství 67:Suppl. C, pages 3-8.
Crossref
Carlota Oleaga, Michael D. Shapiro, Joshua Hay, Paul A. Mueller, Joshua Miles, Cecilia Huang, Emily Friz, Hagai Tavori, Peter P. Toth, Cezary Wójcik, Bruce A. Warden, Jonathan Q. Purnell, P. Barton Duell, Nathalie Pamir & Sergio Fazio. (2021) Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies. Journal of the American College of Cardiology 78:14, pages 1437-1449.
Crossref
BinBin Zheng-Lin & Alberto Ortiz. (2018) Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. Drugs 78:2, pages 215-229.
Crossref
Dhrubajyoti Bandyopadhyay, Kumar Ashish, Adrija Hajra, Arshna Qureshi & Raktim K. Ghosh. (2018) Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering. Journal of Lipids 2018, pages 1-13.
Crossref
Petra El Khoury, Sandy Elbitar, Youmna Ghaleb, Yara Abou Khalil, Mathilde Varret, Catherine Boileau & Marianne Abifadel. (2017) PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies. Current Atherosclerosis Reports 19:12.
Crossref
John J.P. Kastelein, G. Kees Hovingh, Gisle Langslet, Marie T. Baccara-Dinet, Daniel A. Gipe, Umesh Chaudhari, Jian Zhao, Pascal Minini & Michel Farnier. (2017) Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology 11:1, pages 195-203.e4.
Crossref
Marcello Arca. (2017) Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors. Atherosclerosis 256, pages 134-145.
Crossref
Yuichi J. Shimada & Christopher P. Cannon. (2015) PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. European Heart Journal 36:36, pages 2415-2424.
Crossref
Arinze Nkemdirim Okere & Courtney Serra. (2015) Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High‐Risk Cardiovascular Disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35:8, pages 771-779.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.